nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—Differentiation Pathway—ALK—lymphatic system cancer	0.0158	0.97	CbGpPWpGaD
Lenalidomide—Anaemia—Carmustine—lymphatic system cancer	0.000639	0.000649	CcSEcCtD
Lenalidomide—Back pain—Vincristine—lymphatic system cancer	0.000638	0.000649	CcSEcCtD
Lenalidomide—Vomiting—Teniposide—lymphatic system cancer	0.000637	0.000648	CcSEcCtD
Lenalidomide—Sepsis—Methotrexate—lymphatic system cancer	0.000635	0.000646	CcSEcCtD
Lenalidomide—Agitation—Carmustine—lymphatic system cancer	0.000635	0.000645	CcSEcCtD
Lenalidomide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000632	0.000643	CcSEcCtD
Lenalidomide—Asthenia—Fludarabine—lymphatic system cancer	0.000632	0.000643	CcSEcCtD
Lenalidomide—Rash—Teniposide—lymphatic system cancer	0.000632	0.000643	CcSEcCtD
Lenalidomide—Dermatitis—Teniposide—lymphatic system cancer	0.000631	0.000642	CcSEcCtD
Lenalidomide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000629	0.000639	CcSEcCtD
Lenalidomide—Headache—Teniposide—lymphatic system cancer	0.000628	0.000638	CcSEcCtD
Lenalidomide—Pruritus—Fludarabine—lymphatic system cancer	0.000623	0.000634	CcSEcCtD
Lenalidomide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000623	0.000633	CcSEcCtD
Lenalidomide—Back pain—Mitoxantrone—lymphatic system cancer	0.000621	0.000632	CcSEcCtD
Lenalidomide—Leukopenia—Carmustine—lymphatic system cancer	0.000618	0.000629	CcSEcCtD
Lenalidomide—Anorexia—Bleomycin—lymphatic system cancer	0.000616	0.000626	CcSEcCtD
Lenalidomide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000614	0.000624	CcSEcCtD
Lenalidomide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000611	0.000621	CcSEcCtD
Lenalidomide—Anaemia—Vincristine—lymphatic system cancer	0.00061	0.00062	CcSEcCtD
Lenalidomide—Agitation—Vincristine—lymphatic system cancer	0.000606	0.000616	CcSEcCtD
Lenalidomide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000605	0.000615	CcSEcCtD
Lenalidomide—Hypotension—Bleomycin—lymphatic system cancer	0.000604	0.000614	CcSEcCtD
Lenalidomide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000603	0.000613	CcSEcCtD
Lenalidomide—Hypertension—Carmustine—lymphatic system cancer	0.000596	0.000606	CcSEcCtD
Lenalidomide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000596	0.000606	CcSEcCtD
Lenalidomide—Nausea—Teniposide—lymphatic system cancer	0.000595	0.000605	CcSEcCtD
Lenalidomide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000594	0.000603	CcSEcCtD
Lenalidomide—Vertigo—Vincristine—lymphatic system cancer	0.000593	0.000602	CcSEcCtD
Lenalidomide—Hepatic failure—Methotrexate—lymphatic system cancer	0.000591	0.000601	CcSEcCtD
Lenalidomide—Leukopenia—Vincristine—lymphatic system cancer	0.00059	0.0006	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000589	0.000598	CcSEcCtD
Lenalidomide—Chest pain—Carmustine—lymphatic system cancer	0.000588	0.000598	CcSEcCtD
Lenalidomide—Myalgia—Carmustine—lymphatic system cancer	0.000588	0.000598	CcSEcCtD
Lenalidomide—Anxiety—Carmustine—lymphatic system cancer	0.000586	0.000596	CcSEcCtD
Lenalidomide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00058	0.00059	CcSEcCtD
Lenalidomide—Malaise—Mitoxantrone—lymphatic system cancer	0.000579	0.000589	CcSEcCtD
Lenalidomide—Dyspnoea—Bleomycin—lymphatic system cancer	0.000576	0.000585	CcSEcCtD
Lenalidomide—Renal failure acute—Methotrexate—lymphatic system cancer	0.000576	0.000585	CcSEcCtD
Lenalidomide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000575	0.000584	CcSEcCtD
Lenalidomide—Hypertension—Vincristine—lymphatic system cancer	0.000569	0.000579	CcSEcCtD
Lenalidomide—Confusional state—Carmustine—lymphatic system cancer	0.000569	0.000578	CcSEcCtD
Lenalidomide—Oedema—Carmustine—lymphatic system cancer	0.000564	0.000573	CcSEcCtD
Lenalidomide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000562	0.000571	CcSEcCtD
Lenalidomide—Myalgia—Vincristine—lymphatic system cancer	0.000561	0.000571	CcSEcCtD
Lenalidomide—Visual disturbance—Methotrexate—lymphatic system cancer	0.000561	0.00057	CcSEcCtD
Lenalidomide—Cough—Mitoxantrone—lymphatic system cancer	0.00056	0.00057	CcSEcCtD
Lenalidomide—Infection—Carmustine—lymphatic system cancer	0.00056	0.000569	CcSEcCtD
Lenalidomide—Vomiting—Fludarabine—lymphatic system cancer	0.00056	0.000569	CcSEcCtD
Lenalidomide—Rash—Fludarabine—lymphatic system cancer	0.000556	0.000565	CcSEcCtD
Lenalidomide—Dermatitis—Fludarabine—lymphatic system cancer	0.000555	0.000564	CcSEcCtD
Lenalidomide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000555	0.000564	CcSEcCtD
Lenalidomide—Pain—Bleomycin—lymphatic system cancer	0.000552	0.000562	CcSEcCtD
Lenalidomide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000552	0.000561	CcSEcCtD
Lenalidomide—Headache—Fludarabine—lymphatic system cancer	0.000552	0.000561	CcSEcCtD
Lenalidomide—Tachycardia—Carmustine—lymphatic system cancer	0.00055	0.000559	CcSEcCtD
Lenalidomide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000547	0.000556	CcSEcCtD
Lenalidomide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000547	0.000556	CcSEcCtD
Lenalidomide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000547	0.000556	CcSEcCtD
Lenalidomide—Anxiety—Mitoxantrone—lymphatic system cancer	0.000545	0.000554	CcSEcCtD
Lenalidomide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000542	0.000551	CcSEcCtD
Lenalidomide—Lethargy—Methotrexate—lymphatic system cancer	0.000542	0.000551	CcSEcCtD
Lenalidomide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00054	0.000549	CcSEcCtD
Lenalidomide—Oedema—Vincristine—lymphatic system cancer	0.000538	0.000547	CcSEcCtD
Lenalidomide—Anorexia—Carmustine—lymphatic system cancer	0.000537	0.000546	CcSEcCtD
Lenalidomide—Infection—Vincristine—lymphatic system cancer	0.000535	0.000544	CcSEcCtD
Lenalidomide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000532	0.000541	CcSEcCtD
Lenalidomide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000531	0.00054	CcSEcCtD
Lenalidomide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000529	0.000537	CcSEcCtD
Lenalidomide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000528	0.000537	CcSEcCtD
Lenalidomide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000527	0.000536	CcSEcCtD
Lenalidomide—Hypotension—Carmustine—lymphatic system cancer	0.000527	0.000536	CcSEcCtD
Lenalidomide—Oedema—Mitoxantrone—lymphatic system cancer	0.000524	0.000533	CcSEcCtD
Lenalidomide—Nausea—Fludarabine—lymphatic system cancer	0.000523	0.000532	CcSEcCtD
Lenalidomide—Infection—Mitoxantrone—lymphatic system cancer	0.000521	0.000529	CcSEcCtD
Lenalidomide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00052	0.000529	CcSEcCtD
Lenalidomide—Shock—Mitoxantrone—lymphatic system cancer	0.000516	0.000524	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000514	0.000522	CcSEcCtD
Lenalidomide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000513	0.000522	CcSEcCtD
Lenalidomide—Urticaria—Bleomycin—lymphatic system cancer	0.000513	0.000522	CcSEcCtD
Lenalidomide—Anorexia—Vincristine—lymphatic system cancer	0.000513	0.000522	CcSEcCtD
Lenalidomide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000512	0.00052	CcSEcCtD
Lenalidomide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000511	0.000519	CcSEcCtD
Lenalidomide—Insomnia—Carmustine—lymphatic system cancer	0.00051	0.000518	CcSEcCtD
Lenalidomide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000509	0.000518	CcSEcCtD
Lenalidomide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000507	0.000515	CcSEcCtD
Lenalidomide—Paraesthesia—Carmustine—lymphatic system cancer	0.000506	0.000515	CcSEcCtD
Lenalidomide—Mood swings—Methotrexate—lymphatic system cancer	0.000503	0.000512	CcSEcCtD
Lenalidomide—Hypotension—Vincristine—lymphatic system cancer	0.000503	0.000511	CcSEcCtD
Lenalidomide—Dyspnoea—Carmustine—lymphatic system cancer	0.000503	0.000511	CcSEcCtD
Lenalidomide—Somnolence—Carmustine—lymphatic system cancer	0.000501	0.00051	CcSEcCtD
Lenalidomide—Anorexia—Mitoxantrone—lymphatic system cancer	0.0005	0.000508	CcSEcCtD
Lenalidomide—Ataxia—Methotrexate—lymphatic system cancer	0.0005	0.000508	CcSEcCtD
Lenalidomide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000491	0.000499	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00049	0.000499	CcSEcCtD
Lenalidomide—Decreased appetite—Carmustine—lymphatic system cancer	0.00049	0.000498	CcSEcCtD
Lenalidomide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00049	0.000498	CcSEcCtD
Lenalidomide—Insomnia—Vincristine—lymphatic system cancer	0.000487	0.000495	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000487	0.000495	CcSEcCtD
Lenalidomide—Paraesthesia—Vincristine—lymphatic system cancer	0.000483	0.000491	CcSEcCtD
Lenalidomide—Pain—Carmustine—lymphatic system cancer	0.000482	0.00049	CcSEcCtD
Lenalidomide—Constipation—Carmustine—lymphatic system cancer	0.000482	0.00049	CcSEcCtD
Lenalidomide—Breast disorder—Methotrexate—lymphatic system cancer	0.00048	0.000488	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000479	0.000486	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000478	0.000485	CcSEcCtD
Lenalidomide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000476	0.000484	CcSEcCtD
Lenalidomide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000471	0.000478	CcSEcCtD
Lenalidomide—Decreased appetite—Vincristine—lymphatic system cancer	0.000468	0.000476	CcSEcCtD
Lenalidomide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000467	0.000475	CcSEcCtD
Lenalidomide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000466	0.000474	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000465	0.000472	CcSEcCtD
Lenalidomide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000465	0.000472	CcSEcCtD
Lenalidomide—Fatigue—Vincristine—lymphatic system cancer	0.000464	0.000472	CcSEcCtD
Lenalidomide—Asthenia—Bleomycin—lymphatic system cancer	0.000463	0.000471	CcSEcCtD
Lenalidomide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000461	0.000469	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000461	0.000469	CcSEcCtD
Lenalidomide—Pain—Vincristine—lymphatic system cancer	0.00046	0.000468	CcSEcCtD
Lenalidomide—Constipation—Vincristine—lymphatic system cancer	0.00046	0.000468	CcSEcCtD
Lenalidomide—Asthma—Methotrexate—lymphatic system cancer	0.000459	0.000467	CcSEcCtD
Lenalidomide—Pruritus—Bleomycin—lymphatic system cancer	0.000457	0.000465	CcSEcCtD
Lenalidomide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000456	0.000463	CcSEcCtD
Lenalidomide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000452	0.000459	CcSEcCtD
Lenalidomide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00045	0.000458	CcSEcCtD
Lenalidomide—Constipation—Mitoxantrone—lymphatic system cancer	0.000448	0.000456	CcSEcCtD
Lenalidomide—Pain—Mitoxantrone—lymphatic system cancer	0.000448	0.000456	CcSEcCtD
Lenalidomide—Body temperature increased—Carmustine—lymphatic system cancer	0.000446	0.000453	CcSEcCtD
Lenalidomide—Abdominal pain—Carmustine—lymphatic system cancer	0.000446	0.000453	CcSEcCtD
Lenalidomide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00044	0.000448	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00044	0.000447	CcSEcCtD
Lenalidomide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000436	0.000443	CcSEcCtD
Lenalidomide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000432	0.000439	CcSEcCtD
Lenalidomide—Neutropenia—Methotrexate—lymphatic system cancer	0.000429	0.000437	CcSEcCtD
Lenalidomide—Dysuria—Methotrexate—lymphatic system cancer	0.000429	0.000437	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000429	0.000436	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000427	0.000434	CcSEcCtD
Lenalidomide—Abdominal pain—Vincristine—lymphatic system cancer	0.000426	0.000433	CcSEcCtD
Lenalidomide—Body temperature increased—Vincristine—lymphatic system cancer	0.000426	0.000433	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	0.000425	0.0261	CbGpPWpGaD
Lenalidomide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000423	0.00043	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000419	0.000426	CcSEcCtD
Lenalidomide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000416	0.000423	CcSEcCtD
Lenalidomide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000415	0.000422	CcSEcCtD
Lenalidomide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000414	0.000421	CcSEcCtD
Lenalidomide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000414	0.000421	CcSEcCtD
Lenalidomide—Pneumonia—Methotrexate—lymphatic system cancer	0.000412	0.000419	CcSEcCtD
Lenalidomide—Vomiting—Bleomycin—lymphatic system cancer	0.000411	0.000418	CcSEcCtD
Lenalidomide—Infestation—Methotrexate—lymphatic system cancer	0.00041	0.000416	CcSEcCtD
Lenalidomide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00041	0.000416	CcSEcCtD
Lenalidomide—Depression—Methotrexate—lymphatic system cancer	0.000408	0.000415	CcSEcCtD
Lenalidomide—Rash—Bleomycin—lymphatic system cancer	0.000407	0.000414	CcSEcCtD
Lenalidomide—Dermatitis—Bleomycin—lymphatic system cancer	0.000407	0.000414	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000406	0.000413	CcSEcCtD
Lenalidomide—Asthenia—Carmustine—lymphatic system cancer	0.000405	0.000411	CcSEcCtD
Lenalidomide—Renal failure—Methotrexate—lymphatic system cancer	0.000403	0.000409	CcSEcCtD
Lenalidomide—Stomatitis—Methotrexate—lymphatic system cancer	0.000399	0.000406	CcSEcCtD
Lenalidomide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000398	0.000405	CcSEcCtD
Lenalidomide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000397	0.000403	CcSEcCtD
Lenalidomide—Sweating—Methotrexate—lymphatic system cancer	0.000393	0.000399	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—lymphatic system cancer	0.00039	0.000397	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000387	0.000394	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—lymphatic system cancer	0.000386	0.000393	CcSEcCtD
Lenalidomide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000386	0.000393	CcSEcCtD
Lenalidomide—Asthenia—Vincristine—lymphatic system cancer	0.000386	0.000393	CcSEcCtD
Lenalidomide—Diarrhoea—Carmustine—lymphatic system cancer	0.000386	0.000392	CcSEcCtD
Lenalidomide—Nausea—Bleomycin—lymphatic system cancer	0.000384	0.00039	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000382	0.000388	CcSEcCtD
Lenalidomide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000376	0.000382	CcSEcCtD
Lenalidomide—Dizziness—Carmustine—lymphatic system cancer	0.000373	0.000379	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—lymphatic system cancer	0.000369	0.000376	CcSEcCtD
Lenalidomide—Diarrhoea—Vincristine—lymphatic system cancer	0.000368	0.000374	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—lymphatic system cancer	0.000368	0.000374	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—lymphatic system cancer	0.000368	0.000374	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000365	0.000371	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000363	0.000369	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00036	0.000366	CcSEcCtD
Lenalidomide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000359	0.000365	CcSEcCtD
Lenalidomide—Vomiting—Carmustine—lymphatic system cancer	0.000359	0.000364	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—lymphatic system cancer	0.000356	0.000362	CcSEcCtD
Lenalidomide—Rash—Carmustine—lymphatic system cancer	0.000356	0.000361	CcSEcCtD
Lenalidomide—Dermatitis—Carmustine—lymphatic system cancer	0.000355	0.000361	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—lymphatic system cancer	0.000354	0.00036	CcSEcCtD
Lenalidomide—Headache—Carmustine—lymphatic system cancer	0.000353	0.000359	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000348	0.000353	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—lymphatic system cancer	0.000344	0.000349	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—lymphatic system cancer	0.000343	0.000348	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—lymphatic system cancer	0.000342	0.000348	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000341	0.000347	CcSEcCtD
Lenalidomide—Rash—Vincristine—lymphatic system cancer	0.000339	0.000345	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—lymphatic system cancer	0.000339	0.000345	CcSEcCtD
Lenalidomide—Headache—Vincristine—lymphatic system cancer	0.000337	0.000343	CcSEcCtD
Lenalidomide—Nausea—Carmustine—lymphatic system cancer	0.000335	0.00034	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—lymphatic system cancer	0.000334	0.000339	CcSEcCtD
Lenalidomide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000333	0.000339	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000332	0.000338	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000331	0.000337	CcSEcCtD
Lenalidomide—Rash—Mitoxantrone—lymphatic system cancer	0.000331	0.000336	CcSEcCtD
Lenalidomide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00033	0.000336	CcSEcCtD
Lenalidomide—Chills—Methotrexate—lymphatic system cancer	0.00033	0.000335	CcSEcCtD
Lenalidomide—Headache—Mitoxantrone—lymphatic system cancer	0.000328	0.000334	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—lymphatic system cancer	0.000325	0.00033	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—lymphatic system cancer	0.000322	0.000327	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—lymphatic system cancer	0.00032	0.000325	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—lymphatic system cancer	0.00032	0.000325	CcSEcCtD
Lenalidomide—Nausea—Vincristine—lymphatic system cancer	0.00032	0.000325	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000313	0.000319	CcSEcCtD
Lenalidomide—Nausea—Mitoxantrone—lymphatic system cancer	0.000311	0.000317	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—lymphatic system cancer	0.00031	0.000315	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—lymphatic system cancer	0.000302	0.000307	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000297	0.000302	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—lymphatic system cancer	0.000296	0.000301	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—lymphatic system cancer	0.000289	0.000293	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—lymphatic system cancer	0.000288	0.000292	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—lymphatic system cancer	0.000286	0.000291	CcSEcCtD
Lenalidomide—Cough—Methotrexate—lymphatic system cancer	0.000279	0.000284	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—lymphatic system cancer	0.000272	0.000277	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—lymphatic system cancer	0.000272	0.000277	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—lymphatic system cancer	0.000272	0.000277	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000271	0.000275	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—lymphatic system cancer	0.000269	0.000274	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—lymphatic system cancer	0.000263	0.000268	CcSEcCtD
Lenalidomide—Infection—Methotrexate—lymphatic system cancer	0.000259	0.000264	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000256	0.00026	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000256	0.00026	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—lymphatic system cancer	0.000254	0.000258	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000252	0.000257	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—lymphatic system cancer	0.000249	0.000253	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—lymphatic system cancer	0.000244	0.000248	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000238	0.000242	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—lymphatic system cancer	0.000236	0.00024	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000235	0.000238	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000233	0.000237	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—lymphatic system cancer	0.000232	0.000236	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00023	0.000234	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000227	0.000231	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000225	0.000229	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—lymphatic system cancer	0.000225	0.000229	CcSEcCtD
Lenalidomide—Pain—Methotrexate—lymphatic system cancer	0.000223	0.000227	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000215	0.000219	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000214	0.000217	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—lymphatic system cancer	0.000207	0.000211	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000206	0.00021	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000206	0.00021	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000192	0.000196	CcSEcCtD
Lenalidomide—Asthenia—Methotrexate—lymphatic system cancer	0.000187	0.00019	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—lymphatic system cancer	0.000185	0.000188	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000179	0.000182	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—lymphatic system cancer	0.000173	0.000176	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—lymphatic system cancer	0.000166	0.000169	CcSEcCtD
Lenalidomide—Rash—Methotrexate—lymphatic system cancer	0.000165	0.000167	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—lymphatic system cancer	0.000165	0.000167	CcSEcCtD
Lenalidomide—Headache—Methotrexate—lymphatic system cancer	0.000164	0.000166	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—lymphatic system cancer	0.000155	0.000158	CcSEcCtD
Lenalidomide—PTGS2—Disease—NPM1—lymphatic system cancer	5.69e-05	0.0035	CbGpPWpGaD
